Trials / Completed
CompletedNCT03076385
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VAL-506440 | Escalating dose levels |
| OTHER | Placebo |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
- First posted
- 2017-03-10
- Last updated
- 2022-04-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03076385. Inclusion in this directory is not an endorsement.